Navigation Links
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
Date:10/13/2008

robiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, including the inability to enroll patients at anticipated rates, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
3. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
7. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
8. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
9. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
10. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
11. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... AUSTIN, Texas , July 30, 2015 ... solutions company focused on gynecologic disease, announced ... 2015 financial results after the market close ... an investor conference call and webcast at ... August 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
(Date:7/30/2015)... July 30, 2015  NanoSmart Pharmaceuticals, Inc., a ... has received Orphan Drug Designation from the Food ... product that uses NanoSmart,s proprietary drug delivery platform. ... for the treatment of Ewing,s sarcoma, a rare ... NanoSmart,s Orphan Drug Designation on the basis of ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... the release dated August 24, 2011 with the following ... and should read: The Company will provide attendees an ... Form 8K with the SEC after the close of ...  This presentation will also be available at http://ir.questcor.com/sec.cfm ...
... DOYLESTOWN, Pa., Sept. 1, 2011 ProPhase Labs (NASDAQ: ... be donating $1,000 to a well-deserving, locally nominated and ... their "Share Your Cause, Not Your Cold" contest, hosted ... registered, qualified and valid non-for-profit organization organized under the ...
Cached Medicine Technology:UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 2UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 3Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 2Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Women's ... Center for Natural Birth . The Karmanos Center for Natural Birth provides ... experience. With nurses and caregivers that are trained in holistic birth approaches, patients ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers ... Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. Timber frame ... important day for the entire community as the culmination of months of effort, planning, ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled " ... about a woman’s unfortunate experience having cosmetic skin procedures done by a family ... in blistering, swelling, bruising, and pain. This woman’s experience is only one in ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... to Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., ... IDMI ) today announced that the European ... MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with ... tumor that typically affects children and young adults. ...
... Clinic Proceedings author reviews the consequencesROCHESTER, Minn., March ... hospital before the treating physician recommends discharge, the ... conditions and the need for readmission, according to ... Mayo Clinic Proceedings. Additionally, the article examines the ...
... 9 Nancy Brinker, famed breast cancer activist and ... be the 2009 recipient of the University of Pittsburgh ... recognition of her outstanding achievements promoting health and preventing ... nearly 30 years ago when she promised her dying ...
... Two Japanese scientists will arrive at the University of ... device that promises to deliver more comprehensive and accurate ... cost of current technologies. , In April, Mikio Kubota ... will join the research team at UH,s Biomedical Imaging ...
... Michigan Catholic Conference Vice President for Public Policy ... regarding an executive order to be issued by ... embryonic stem cell research:"President Obama,s executive order regrettably ... scientific therapeutic advancements. There are endless studies ...
... with MEDITECH Magic through Interface from Iatric Systems, ... Corporation , a leading provider of handheld, ... announced that Ottawa Regional Hospital & Healthcare ... its Barcode Point-of-Care (BPOC) provider to improve bedside ...
Cached Medicine News:Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3Health News:Nancy Brinker to receive 2009 Porter Prize 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 2Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 3Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 4
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
... The Ichor hematology instrument is a ... When used with Plateletworks reagents, the Ichor ... standard CBC with platelet count plus platelet ... simple. A fresh whole blood sample is ...
... family, which includes the world's smallest ... most advanced pacemaker technology available, including ... first and only U.S. commercially approved ... (AF). The AF Suppression algorithm in ...
... CryoTherapy system uses catheters that are ... refrigeration console. The console processes the ... distal tip of the catheter, creates ... through an easy-to-use touch-screen interface. From ...
Medicine Products: